Importantly, we provided evidence that AZD1480 (in STAT3-high GBM cells) and AZD1480/Linsitinib (in STAT3-low GBM cells) synergized with TMZ to mitigate in vitro tumor cell viability. This evidence concerns the gene STAT3 and glioblastoma.